- Home
- Companies
- Veracyte
- Applications
- Immunoscore for Colon Cancer Patients - ...
Immunoscore for Colon Cancer Patients - Medical / Health Care - Clinical Services
To date, the classification of cancers has been based solely on the phenotypic and genotypic characteristics of tumor cells. A new paradigm, scientifically well established and recommended by WHO guidelines, relies on the introduction of the immune response as a new prognostic parameter to predict and refine the clinical outcomes of cancer patients. Maximize patient survival rates with an assessment of the tumor immune response.
Immunity assessed, Personalized treatment
Immunoscore® is a test, recently included within ESMO guidelines, that predicts the risk of relapse in patients with localized colon cancer thereby facilitating the chemotherapy decision-making process.
Validated in a large international study conducted on more than 2500 Stage I-III colon cancer patients (Pagès et al, The Lancet 2018), Immunoscore® was demonstrated to be a powerful and independent prognostic factor for patient survival, providing the greatest contribution to patient prognostication of all assessed factors.
How can Immunoscore® help patient management? With localized colon cancerIntroducing Immunoscore® into routine clinical practice at diagnosis gives oncologists access to precision medicine for improving cancer management outcomes and can help to facilitate:
- Refinement of patient risk profiles by providing a greater prognostic value compared to traditional measurements.
- Adjustment of treatment decisions and improved colon cancer patient management.
- Prediction of the most effective treatment duration.
- Personalization of patient follow-ups